A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma Interventions:   Radiation: Intensity-modulated radiotherapy (IMRT);   Drug: Tislelizumab;   Drug: Cisplatin;   Drug: Nab paclitaxel Sponsor:   Renmin Hospital of Wuhan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials